AUA2025: John K Lattimer Lecture: Telesurgery

AUA2025: Key Takeaways: Female Urology Highlights Presenter: Mitch G. Goldenberg, MD & Kathleen Kobashi, MD, MBA, FACS

AUA2025: John Duckett Memorial Lecture: Obstructive Bladder Disease: Molecular Insights and Therapeutic Opportunities Presenter: Rosalyn M. Adam, PhD

AUA2025: Ramon Guiteras Lecture: The Future of Healthcare: How Will Urology be Impacted? Presenter: Vin Gupta, MD, MPA

AUA2025: John K Lattimer Lecture: Telesurgery Presenter: Vipul Patel, MD

Contemporary Management of MIBC and Beyond: Expert Guidance for Urologists (Republished) CME Available: auau.auanet.org/node/42040 After participating in this CME activity, participants will be able to: 1. Describe the multimodal treatment approach for MIBC, including surgery, radiation therapy, and chemotherapy. 2. Analyze the role of neoadjuvant and adjuvant therapies, including chemotherapy, immunotherapy, and antibody drug conjugates, in improving patient outcomes. 3. Utilize knowledge of checkpoint inhibitors and antibody drug conjugates with their mechanisms of action to interpret the role of immunotherapy in the treatment of metastatic urothelial carcinoma. 4. Examine ongoing clinical trials and emerging treatments that are shaping the future of metastatic urothelial carcinoma management. 5. Employ appropriate patient and family education strategies regarding MIBC and metastatic urothelial carcinoma, treatment options, and expected outcomes. Acknowledgements Support provided by an independent educational grant from: Astellas and Pfizer, Inc.

AUA2025: Chemotherapy and Immunotherapy for Urologists and Advanced Practice Providers (APPs) CME Available: https://auau.auanet.org/node/43009 At the conclusion of this activity, participants will be able to: 1. Identify the guidelines for first-line and beyond treatment of patients with hormone-sensitive advanced and metastatic prostate cancer, including medications, their mechanism, side effects and efficacy. 2. Summarize the recommendations for first-line and beyond treatment of castrate-resistant metastatic and nonmetastatic prostate cancer, including medications, their mechanism, side effects and efficacy. 3. Diagram the treatment options for high-risk non-muscle invasive bladder cancer. 4. Distinguish the guideline-defined therapeutic options for locally advanced and metastatic bladder cancer. 5. Discuss treatment options for locally advanced and metastatic kidney cancer, including medications, their mechanism, side effects and efficacy. ACKNOWLEDGEMENTS: This educational activity is supported by independent educational grants from: Astellas, Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC, Lantheus Medical Imaging, Novartis Pharmaceuticals Corporation, Pfizer, Inc.

Update Series (2025) Lesson 18: Multidisciplinary Evaluation and Management of Pelvic Pain in Women Now in its 44th installment, the AUA Update Series is renowned for delivering high-quality lessons to practicing urologists, fellows and residents. All content is developed by internationally recognized experts in urology, making the AUA Update Series the most professional and sought-after self-study program available. Improve your practice and patient care by staying abreast of the latest treatments and surgical techniques in urology. For more information or to subscribe to the AUA Update Series, please visit AUAnet.org/Update25

AUA2025: Incorporating Genomic Testing and Advanced Imaging for Prostate Cancer Into Your Practice CME Available: https://auau.auanet.org/node/43029 At the conclusion of this activity, participants will be able to: 1. Describe the research that led to the approval of genomic testing for prostate cancer and the implementation of advanced imaging for prostate cancer 2. Order appropriate genomic testing and advanced imaging based on a patient's unique clinical situation 3. State the NCCN guidelines for genomic testing and advanced imaging for prostate cancer 4. Discern the different prognostic endpoints provided by various genomic tests 5. Recognize candidates for, and implications of, germline testing for prostate cancer. ACKNOWLEDGEMENTS: This educational activity is supported by independent educational grants from: Astellas, Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC, Lantheus Medical Imaging, Novartis Pharmaceuticals Corporation, Pfizer, Inc.

AUA2025: Management of Non-Muscle Invasive Bladder Cancer: Practical Solutions for Common Problems  CME Available: https://auau.auanet.org/node/43047 At the conclusion of this activity, participants will be able to: 1. Implement current practice guidelines and explain methods and resources to improve transurethral resection of a bladder tumor (TURBT) skills. 2. Identify the best intravesical agent and duration of therapy for low-, intermediate-, and high-risk NMIBC and what to do during a BCG shortage. 3. Identify methods to treat significant toxicities from various intravesical therapies. 4. Define high-risk scenarios that necessitate cystectomy and options for BCG-unresponsive disease. 5. Identify the scientific rationale for investigating immune oncology agents for BCG-unresponsive disease and become familiar with current clinical trial designs. ACKNOWLEDGEMENTS: This educational activity is supported by an independent educational grants from: Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC.

The Surgical Management of BPH (2025) CME Available: https://auau.auanet.org/node/43193 Acknowledgements: This educational series is supported by an independent educational grant from Olympus Corporation of the Americas. After participating in this CME activity, participants will be able to: 1. Utilize the AUA Clinical Guideline on the Management of Lower Urinary Tract Symptoms Attributed to Benign Prostatic Hyperplasia in practice. 2. Determine the appropriate role and clinical expectation for current technologies, including pivotal studies, based on evidence. 3. Interpret the current clinical results and compare the patient experiences of these treatments in relation to more established and even abandoned treatments for patient groups with similar characteristics. 4. Differentiate between each of the new technologies for treating BPH/LUTS based on both their mode-of-action and the quality of their supporting evidence.